COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00936143
Recruitment Status : Completed
First Posted : July 9, 2009
Last Update Posted : January 26, 2016
Information provided by (Responsible Party):
Gu Jieruo, Sun Yat-sen University

Brief Summary:
This is a prospective open-label study to evaluated the efficacy and safety of infliximab(Remicade) in treating of patients with early ankylosing spondylitis (AS). Infliximab was injected intra-venous on baseline, 2nd week, 6th week, 12th week and 24th week, with dosing of 5mg/kg. The major outcome index is ASAS20, and minor outcome indexes include ASAS50 and ASAS70, BASDAI20,BASDAI50 and BASDAI70. And MRI of sacroiliac joint is not necessary. The adverse events at any time were recorded.

Condition or disease Intervention/treatment Phase
Spondylitis Drug: infliximab Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis
Study Start Date : January 2008
Actual Primary Completion Date : September 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Infliximab

Arm Intervention/treatment
Experimental: infliximab
200mg infliximab inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
Drug: infliximab
100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
Other Name: remicade

Primary Outcome Measures :
  1. Proportion of patients achieving ASAS20 improvement. [ Time Frame: 6th week ]

Secondary Outcome Measures :
  1. Proportion of patients achieving ASAS50 and ASAS70 [ Time Frame: 6th week and 24 week. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 16 to 65 years old, having signed the informed consent;
  2. fulfill the ESSG criteria for diagnosis of SpA; not fulfill the 1984 modified NewYork criteria for AS;
  3. have inflammatory back pain defined by Calin criteria;
  4. disease duration range from 6 months to 2 years;
  5. BASDAI score more than 4;
  6. MRI score of sacroiliac joint more than 4;
  7. lab examination: hemoglobin more than 90 gram/liter. Aspartate aminotransferase and Alanine aminotransferase less than 2 fold of upper level of normal range. Creatine less than upper level of normal range.

Exclusion Criteria:

  1. History of psoriasis or inflammatory bowel disease.
  2. Intra-articular injection of cortisone within 3 months.
  3. Patients were taking cortisone, SASP or MTX, unless the dose has been stable for at least 3 months.
  4. Active iritis.
  5. History of heart failure, multiple sclerosis, COPD, lymphoma or other tumor, tuberculosis.
  6. Female of pregnancy or breast feeding.
  7. History of mental disease and poor compliance.
  8. History of drug abuse or alcoholism.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00936143

Layout table for location information
China, Guangdong
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630
Sponsors and Collaborators
Gu Jieruo
Layout table for additonal information
Responsible Party: Gu Jieruo, Rheumatology Department, Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University Identifier: NCT00936143    
Other Study ID Numbers: REM-CHN-IIS-01
First Posted: July 9, 2009    Key Record Dates
Last Update Posted: January 26, 2016
Last Verified: January 2016
Keywords provided by Gu Jieruo, Sun Yat-sen University:
Spondylitis, Ankylosing
Antibodies, Monoclonal
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis, Ankylosing
Bone Diseases, Infectious
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Joint Diseases
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents